Key Insights

Highlights

Success Rate

96% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

3.2%

1 terminated out of 31 trials

Success Rate

96.0%

+9.5% vs benchmark

Late-Stage Pipeline

45%

14 trials in Phase 3/4

Results Transparency

42%

10 of 24 completed with results

Key Signals

10 with results96% success

Data Visualizations

Phase Distribution

28Total
Not Applicable (2)
Early P 1 (2)
P 1 (6)
P 2 (4)
P 3 (8)
P 4 (6)

Trial Status

Completed24
Unknown4
Recruiting1
Not Yet Recruiting1
Terminated1

Trial Success Rate

96.0%

Benchmark: 86.5%

Based on 24 completed trials

Clinical Trials (31)

Showing 20 of 20 trials
NCT07300267Phase 1RecruitingPrimary

A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)

NCT06177912Phase 3CompletedPrimary

A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)

NCT05696080Phase 3CompletedPrimary

Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)

NCT06817421Phase 4Not Yet Recruiting

Opportunistic Pneumococcal Immunisation Trial in MALnutrition

NCT05158140Phase 3CompletedPrimary

Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)

NCT03489018Phase 4CompletedPrimary

The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants

NCT05425732Phase 3CompletedPrimary

Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)

NCT04665050Phase 1CompletedPrimary

Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)

NCT03619252Phase 4Completed

Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents

NCT02279589Phase 2CompletedPrimary

Open Randomized Trial Evaluating Four Anti-pneumococcal Vaccine Strategies With Fractionated Doses of Non Conjugate Polysaccharide Vaccine to Prevent Hyporesponse in Healthy Volunteers

NCT01863719Phase 1Terminated

Aerosolized and Intravenous Colistin in Healthy Adults

NCT03467984Phase 2CompletedPrimary

A Study to Evaluate the Safety and Immunogenecity of LBVE(Multivalent Pneumococcal Conjugate Vaccine) in Healthy Infants

NCT02260882Phase 4CompletedPrimary

Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902)

NCT01307449Not ApplicableCompletedPrimary

Systems Biology of PNEUMOVAX®23 and PREVNAR 13®

NCT01531322Phase 1CompletedPrimary

A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Subjects

NCT03549208Phase 1UnknownPrimary

A Study to Evaluate the Safety and Immunogeneicity of Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults

NCT03341195Not ApplicableUnknown

Mobile Phone SMS Messages and Automated Calls in Improving Vaccine Coverage Among Children in Pakistan

NCT00535730Phase 3Completed

ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)

NCT00560950Phase 3CompletedPrimary

Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007)

NCT03095326Phase 4Completed

Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia

Scroll to load more

Research Network

Activity Timeline